BioSpecifics Technologies Corp. to Webcast, Live, at on December 6th

             BioSpecifics Technologies Corp. to Webcast, Live, at
       on December 6th

Main Street and Wall Street investors to attend interactive real-time virtual

PR Newswire

NEW YORK, Dec. 4, 2012

NEW YORK, Dec. 4, 2012 /PRNewswire/ -- is
pleased to announce that BioSpecifics Technologies Corp. (NASDAQ: BSTC), a
biopharmaceutical company developing first in class collagenase-based products
marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, will
present at BioSpecifics' President Tom L.
Wegman will be speaking directly to investors.

DATE:  December 6, 2012
TIME:  3:00 PM EST
LINK: > red "register / watch event now"

This will be a live, interactive online event where investors are invited to
ask the company questions in real-time - both in the presentation hall as well
as the company's "virtual trade booth." If attendees are not able to join the
event live on the day of the conference, an on-demand archive will be
available for 90 days.

It is recommended that investors pre-register to save time and receive event

BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. (Nasdaq GM: BSTC) is a biopharmaceutical
company that has developed injectable collagenase for twelve clinical
indications. Injectable collagenase is currently marketed as XIAFLEX® in the
U.S. for the treatment of adult Dupuytren's contracture patients with a
palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is approved for
Dupuytren's contracture in the European Union and Canada. XIAFLEX is also in
clinical development for the treatment of several additional promising
indications: Auxilium recently submitted a supplemental Biologics License
Application (sBLA) to the FDA for XIAFLEX for the potential treatment of
Peyronie's disease based on positive results reported from its two Phase III
clinical studies. Auxilium is also testing XIAFLEX for frozen shoulder
syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib
clinical trials, respectively. BioSpecifics is currently managing the clinical
development of XIAFLEX for the treatment of human lipoma and canine lipoma,
which are both in Phase II clinical trials. Auxilium is currently partnered
with Asahi Kasei Pharma Corporation for the development and commercialization
of injectable collagenase for Dupuytren's contracture and Peyronie's disease
in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in
Canada, Australia, Brazil and Mexico. Pfizer Inc. has marketing rights to
XIAPEX® (the EU trade name for XIAFLEX) for Dupuytren's contracture in 46
countries in Eurasia through April 24, 2013. For more information, please


Since 2010, has been the only monthly virtual
investor conference series that provides an interactive forum for presenting
companies to meet directly with retail investors using a graphically-enhanced
online platform.

Designed to replicate the look and feel of location-based investor
conferences, Retail Investor Conferences unites PR Newswire's leading-edge
online conferencing and investor communications capabilities with
BetterInvesting's extensive retail investor audience network.


Contact: Thomas L. Wegman, President, BioSpecifics Technologies Corp.,
+1-516-593-7000,; or Bradley H. Smith,,, +1-201-942-7157
Press spacebar to pause and continue. Press esc to stop.